Oxidative modification of fibrinogen is associated with altered function and structure in the subacute phase of myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 7, 2014, Pages 1355-1361

  Becatti, Matteo ^a   Marcucci, Rossella ^a   Bruschi, Giulia ^a   Taddei, Niccolò ^a   Bani, Daniele ^a   Gori, Anna Maria ^a,b   Giusti, Betti ^a   Gensini, Gian Franco ^a,b   Abbate, Rosanna ^a   Fiorillo, Claudia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

fibrinogen; myocardial infarction; oxidative stress

Indexed keywords

FIBRINOGEN; PLASMIN; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CIRCULAR DICHROISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL INTERFERENCE CONTRAST MICROSCOPY; ELECTRON MICROSCOPY; FEMALE; FIBRIN POLYMERIZATION; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MALE; MICROSCOPY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN SECONDARY STRUCTURE;

FIBRINOGEN; MYOCARDIAL INFARCTION; OXIDATIVE STRESS;

AGED; BLOOD COAGULATION; CASE-CONTROL STUDIES; CIRCULAR DICHROISM; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMANS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, INTERFERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROTEIN CARBONYLATION; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84903139518     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303785     Document Type: Article

References (34)

1. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52:601-623.
2. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-1478.
3. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part II: animal and human studies. Circulation. 2003;108:2034-2040.
4. Undas A, Szu?drzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2008;196:551-557.
5. Tanaka S, Miki T, Sha S, Hirata K, Ishikawa Y, Yokoyama M. Serum levels of thiobarbituric acid-reactive substances are associated with risk of coronary heart disease. J Atheroscler Thromb. 2011;18:584-591.
6. Becatti M, Fiorillo C, Gori AM, Marcucci R, Paniccia R, Giusti B, Violi F, Pignatelli P, Gensini GF, Abbate R. Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. Atherosclerosis. 2013;231:392-400.
7. Paton LN, Mocatta TJ, Richards AM, Winterbourn CC. Increased thrombin- induced polymerization of fibrinogen associated with high protein carbonyl levels in plasma from patients post myocardial infarction. Free Radic Biol Med. 2010;48:223-229.
8. Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, Zhou ZM, Zhou M, Xie D, Wang GB, Zhang X. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:1156-1162.
9. Simon AS, Chithra V, Vijayan A, Dinesh RD, Vijayakumar T. Altered DNA repair, oxidative stress and antioxidant status in coronary artery disease. J Biosci. 2013;38:385-389.
10. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ; AtheroGene Investigators. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med. 2003;349:1605-1613.
11. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007;49:1993-2000.
12. Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med. 1994;17:429-437.
13. Olinescu RM, Kummerow FA. Fibrinogen is an efficient antioxidant. J Nutr Biochem. 2001;12:162-169.
14. Rondeau P, Navarra G, Cacciabaudo F, Leone M, Bourdon E, Militello V. Thermal aggregation of glycated bovine serum albumin. Biochim Biophys Acta. 2010;1804:789-798.
15. Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci. 2008;38:15-23.
16. Shacter E, Williams JA, Levine RL. Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med. 1995;18:815-821.
17. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids. 2003;25:207-218.
18. Cai Z, Yan LJ. Protein oxidative modifications: beneficial roles in disease and health. J Biochem Pharmacol Res. 2013;1:15-26.
19. Davies KJ, Delsignore ME, Lin SW. Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J Biol Chem. 1987;262:9902-9907.
20. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med. 2006;10:389-406.
21. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev. 2000;32:307-326.
22. Gallwitz M, Enoksson M, Thorpe M, Hellman L. The extended cleavage specificity of human thrombin. PLoS One. 2012;7:e31756.
23. Serneri GG, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B, Dabizzi P, Poggesi L, Modesti PA, Trotta F. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation. 1992;86:790-797.
24. Miniati M, Fiorillo C, Becatti M, Monti S, Bottai M, Marini C, Grifoni E, Formichi B, Bauleo C, Arcangeli C, Poli D, Nassi PA, Abbate R, Prisco D. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med. 2010;181:992-996.
25. Undas A, Ariens RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011;31:e88-e99.
26. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26:2567-2573.
27. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol. 2011;31:494-499.
28. Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, Kearney MT, Ariens RA, Grant PJ. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol. 2009;29:712-717.
29. Scott EM, Ariens RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:1558-1566.
30. Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost. 1996;76:535-540.
31. Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J. 1992;63:111-128.
32. Fatah K, Hamsten A, Blomback B, Blomback M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost. 1992;68:130-135.
33. Langer BG, Weisel JW, Dinauer PA, Nagaswami C, Bell WR. Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem. 1988;263:15056-15063.
34. He S, Bark N, Wang H, Svensson J, Blomback M. Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis. J Cardiovasc Pharmacol. 2009;53:24-29.